Stocks and Investing Stocks and Investing
Fri, June 17, 2022
Thu, June 16, 2022
Wed, June 15, 2022
Tue, June 14, 2022
Mon, June 13, 2022

Jasper Hellweg Maintained (VRTX) at Strong Buy with Increased Target to $280 on, Jun 13th, 2022


Published on 2024-10-27 21:29:36 - WOPRAI, Jasper Hellweg
  Print publication without navigation


Jasper Hellweg of Argus Research, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $275 to $280 on, Jun 13th, 2022.

Jasper has made no other calls on VRTX in the last 4 months.



There are 12 other peers that have a rating on VRTX. Out of the 12 peers that are also analyzing VRTX, 6 agree with Jasper's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $267 on, Sunday, June 12th, 2022
  • David Risinger of "SVB Leerink" Initiated at Hold and Held Target at $265 on, Monday, May 23rd, 2022
  • Do Kim of "Piper Sandler" Maintained at Hold with Decreased Target to $242 on, Friday, May 6th, 2022
  • Brian Skorney of "Baird" Downgraded from Buy to Hold on, Friday, May 6th, 2022
  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $240 on, Thursday, May 5th, 2022
  • Matthew Harrison of "Morgan Stanley" Upgraded from Sell to Hold and Held Target at $250 on, Tuesday, May 3rd, 2022


These are the ratings of the 6 analyists that currently disagree with Jasper


  • Jason McCarthy of "Maxim Group" Upgraded from Hold to Strong Buy and Held Target at $325 on, Wednesday, June 1st, 2022
  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $278 on, Tuesday, May 24th, 2022
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $305 on, Friday, May 6th, 2022
  • Gena Wang of "Barclays" Maintained at Buy and Held Target at $291 on, Thursday, May 5th, 2022
  • Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $322 on, Wednesday, April 27th, 2022
  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $350 on, Monday, April 4th, 2022